Method of treating lipidosis and body-weight reduction in patients with cardiovascular diseases

FIELD: medicine.

SUBSTANCE: treating of lipidosis and body-weight reduction in the patients with cardiovascular diseases is ensured by diet therapy based on the lacto-vegetarian diet. It involves introduction of proteins in daily amount of 67-79 g, including animal 48-57%, fats in daily amount of 32-49 g, including animal 40-52%, carbohydrates in daily amount of 240-257 g, cholesterol in daily amount of 40-268 mg, cellulose in daily amount of 18-20 g, dietary fibers in daily amount of 150 mg, potassium (K) in daily amount of 4567-6433 mg, magnesium (Mg) in daily amount of 535-693 mg, vitamin E in daily amount of 44-53 mg, arginine in daily amount of 3.9-5.2 g, dehydrated powdered maral meat in daily amount of 1200 mg, microcrystalline cellulose in daily amount of 900 mg. Duration of the diet therapy course is 33 days.

EFFECT: method provides suppression of cholesterol biosynthesis and intensification of excretion thereof that reduces the atherogenic index, reduces manifestations of oxidative stress, with reduced risk of realisation of the modified factors of a cardiovascular pathology.

1 tbl

 

The invention relates to medicine, namely to the diet, and is a method of treating diseases associated with lipid metabolism, in particular, in patients with atherosclerosis, hypertension, coronary heart disease, obesity. Currently widely discussed the possibility of preventing the development of atherosclerosis, treatment of associated diseases and complications. In domestic and foreign literature there are many reports on the use of medicinal and non-medicinal effects for the normalization of lipid metabolism [1, 2].

Known antihyperlipidemics means different mechanism of action:

group 1: statins (inhibitors of 3-hydroxy-3-methylglutaryl-COA reductase) - inhibit the biosynthesis of cholesterol. Drugs: lovastatin, medostatin, mevacor, zocor, pravastatin, lescol.

2nd group: anion-exchange resin (biliary acids), insoluble in water, they bind bile acids in the intestine, preventing their reabsorption, and in the synthesis of bile acids requires more cholesterol on cell membranes increases the number of receptors for low-density lipoproteins, which reduces the level of circulating cholesterol low density lipoprotein. Drugs: colestipol, cholestyramine.

Group 3:nicotinic acid water-soluble vitamin that lowers cholesterol very low density lipoprotein and low-density lipoprotein, moderately reduces total cholesterol and triglycerides (mostly), and also increases the level of cholesterol high density lipoprotein. Drugs in this group are olbetam, enduracin.

4th group: fibrates - mainly reduce the level of triglycerides and moderately cholesterol. Drugs: gemifibrozil, bezafibrat, ciprofibrate[3, 4, 5, 6].

From vegetable raw materials created several medicines with antihyperlipidemic activity. These include palilonis, tribosphenic [5].

However, these medications have some common side effects for all drugs: bloating, vomiting, heartburn, hiccups, belching, constipation, nausea, abdominal pain, insomnia. May develop hypersensitivity to the development of anaphylaxis and angioedema[3, 4, 5, 6]. During treatment with statins in 1-2% of patients with transaminases exceed the upper limit of normal is more than 3 times within 15 months after the start of treatment. 2% of patients are myalgia, myositis, noted the increased activity of CPK in blood and muscle tissue. Described cases of acute necrosis of skeletal muscles. Therefore, statins with caution is thew prescribed to patients with liver disease, alcohol abuse, arterial hypotension, severe infection, epilepsy, trauma and the need for large surgical interventions.

On a background of reception of anion-exchange resins (bile acid sequestrants) may develop anorexia, dysphagia, diarrhea, ileus, bleeding due to a deficiency of vitamin K, the increase in body mass. The reception of these medicines can sometimes contribute to the formation of peptic ulcers, pancreatitis.

Fibrates increase the frequency of formation of gallstones. General contraindications for drugs of all groups are: liver disease in the acute stage, pregnancy, complete obstruction of the biliary tract, exacerbation of peptic ulcer, diabetes mellitus, gout, severe heart rhythm disturbances [7].

It should be noted that one of the features of medication therapy and prevention of the atherosclerotic process (hyperlipoproteinemias) is that the normalizing effect of drugs on blood lipids is observed only in the period when the patient accepts them. After the drug content of blood lipid gradually returns to the original level. In regard to the appointment of medicines for many years, and sometimes the whole life and [8]. This, in turn, in addition to worsening of side effects and cause large amounts of money for treatment.

Along with medication used with diet therapy. It is known that the level of blood lipids depends on the nature of power. Known diets focus on limiting caloric intake, intake of fats and carbohydrates. So, widely used mixed protivoateroskleroticheskim diet No. 10C, developed by the Institute of nutrition of Russian Academy of medical Sciences. Used in ischemic heart disease, atherosclerosis of the coronary, cerebral, peripheral vascular hypertension II and stage III, patients with excessive body weight [8].

Diet No. 10C includes meat and fish products, and products of vegetable origin. Diet is balanced and widely used in the treatment of patients with disorders of lipid metabolism. However, the practical application of such diets have shown that the presence of meat and fish products that are rich in nitrogenous extractive substances, purine and pyrimidine bases containing large amounts of proteins and fats of animal origin with a high concentration of cholesterol, low levels of macro - and microelements, as well as a clear lack of fiber content, does not provide tangible results for patients with impaired lipid is the second currency.

The priority of cardiovascular disease in the General structure of morbidity and the leading position of these diseases as causes of premature mortality suggest any attempts to develop new means of prevention and treatment of socially and economically important area in clinical practice[1, 2, 7].

The closest achieved a positive result (the prototype) is a method of treatment of lipid metabolism disorders in patients with cardiovascular diseases, which is to assign the diet with additional product containing dried defibrinating the blood of deer and nicotinic acid in the following ratio of components, %of: dried defibrinated blood red 99,0-1,0, nicotinic acid and 1.0-99,0 [9].

However, this method of treatment of disorders of lipid metabolism has several disadvantages: low efficiency of treatment, side effects of nicotinic acid, namely redness of the face and the upper half of the body, especially when taken on an empty stomach and with high sensitivity, dizziness, feeling the rush of blood to the head, rash, and itching of the skin, gastrointestinal disorders, paresthesia, urticaria, orthostatic hypotension. With long - term use liver dystrophy, reduced glucose tolerance, up to hyperglycemia, above the s content in the blood of some enzymes (aspartic transaminase levels LDH, alkaline phosphatase) [1, 4, 5]. Also, this method of treatment does not allow simultaneous effective weight loss that allows you to develop and progress related cardiovascular disease.

Thus, the search for new effective ways of correction of dyslipidemia and reduce the risk of implementation of modified factors of cardiovascular disease is an important task. The authors propose a new method that extends the capabilities of diet in the prevention and treatment of patients with cardiovascular diseases associated with lipid metabolism disorders, based on the decrease in the influx of cholesterol from food in the body of the patient, the inhibition of cholesterol biosynthesis in the liver, increased conversion of cholesterol into bile acids with a view to their removal, enhancing the mechanical removal of cholesterol by its adsorption on dietary fibers, eliminating microelements K, Fe, Mg, vitamin E deficiency of the amino acid arginine. The problem is solved in that diet therapy is performed on the basis of lactovegetarians diet, including in products of plant origin (fruits, vegetables, grains, legumes, and dairy products, potassium (K) 4567-6433 mg per day of magnesium (Mg) 535-693 mg per day, vitamin E 44-53 mg per day, arginine of 3.9 to 5.2 grams per day. In addition, di the political activities included dehydrated powder meat deer - 1200 mg per day and microcrystalline cellulose - 900 mg per day in the form of, for example, specialized food "Meat Altai maral", containing one capsule following ingredients: dehydrated powder meat deer - 200 mg microcrystalline cellulose - 150 mg. Dose of 2 capsules three times daily by mouth, in a period of 33 days.

The use of the proposed method as a means of correction of dyslipidemia, and body weight reduction was possible thanks to clinical research. A clinical study was conducted in the conditions of therapeutic Department of the polyclinic No. 1 public health "Department of clinical hospital station Barnaul", clinical Altai state medical University and was a randomized, controlled study. Patients randomly divided into two groups (25 patients in each type of additions to the standard therapeutic intervention). Patients included in the research group were diagnosed to have hypertension: III stage, III phase, high risk and those associated pathological processes such as ischemic heart disease: angina, functional class II-III, III degree obesity. Age range 42-60 years. Course Leche is ment lasted 33 days. Clinical examination in terms of tolerability of treatment, treatment effectiveness was carried out at 3, 15, 33 the day of the doctor and the research coordinators. Biochemical laboratory tests were conducted according to the standard clinic procedures. According to the results of biochemical studies of blood patients divided into 2 groups according to the degree of lipid metabolism. I group with type IIA dyslipidemia was 27; group II with dyslipidemia type II b - 23. Menu lactovegetarians diet group I patients (main) contained proteins from 67 to 79 g / day, of which animals 48-57%, fat 32-49 grams per day, of which animals 40-52%, carbohydrates 240-257 grams per day. Caloric intake 1210-1460 kcal, cholesterol 40-268 mg per day. The fiber 18 to 20 g per day of dietary fiber 150 mg daily, potassium (K) 4567-6433 mg per day of magnesium (Mg) 535-693 mg per day, vitamin E 44-53 mg per day, arginine of 3.9 to 5.2 grams per day, dehydrated powder meat deer 1200 mg per day, microcrystalline cellulose 900 mg per day. A mixed diet in group II (comparison) proteins 69-75 grams per day, of which animals 69-74%, fats 30-55 grams per day, of which animals 82-91%, carbohydrates 252-296 grams per day. Caloric intake 1620-1817 kcal. Cholesterol 236-594 mg/day, fiber 8-10 grams per day.

As can be seen from the above data, the proposed balanced protivoepidemichesky diet with the contains protein and fat is roughly equivalent to the number of mixed diet, but the percentage of proteins and fats of vegetable origin in protivoepidemicheskoj diet, respectively, 1.6 and 2.1 times more. Such a high content of vegetable fats helps to reduce receipt of exogenous cholesterol from food is approximately 2-5 times. In addition, the high content of the amino acid arginine (protivoepidemicheskaja diet of 3.9 to 5.2 g, a mixed diet of 2.4-2.7 g) increases the level of arginine in the blood, which stimulates the secretion of the pancreatic hormone glucagon, which inhibits the activity of the key enzyme (β-hydroxide-β-methylglutaryl COA-reductase is responsible for the speed of the biosynthesis of cholesterol in the body. Protivoepidemicheskaja diet containing vegetable fats rich in polyunsaturated fatty acids (3-5 times more than in the mixed ration), facilitates the connection of cholesterol with polyunsaturated fatty acids, making it easier metabolized and excreted from the body.

Protivoepidemichesky diet contains significantly more potassium than mixed, which improves contractile function of the myocardium, which helps normalize blood flow and prevents the absorption of cholesterol in the vascular wall. Great value for the normalization of cholesterol metabolism has content in the diet of vitamin E. Proteolipid hemicheskiy diet 6-7 times richer mixed vitamin E, that leads to lower level of cholesterol in the blood, as vitamin E reduces manifestations of oxidative stress damage of the epithelium of blood vessels, is an inhibitor of cholesterol synthesis. The level of iron in lipid-lowering diet is also more than 3 times higher compared to the mixed magnesium more than 1.5 times. It is known that iron and magnesium have an inhibitory effect on the formation of neutral fat.

It is also known that dietary fiber stimulates the motor-evacuation function of the bowel, that is exempt from faeces and a range of toxic substances, normalize the intestinal microflora involved in the formation of secondary bile acids from the primary, thereby helping to eliminate cholesterol from the body. A vegetarian diet contains 2 times more fiber than mixed. Stimulating the motor-evacuation function, dietary fiber and dietary fiber are the matrix, which is adsorbed cholesterol and korostelina removed in the composition of the fecal mass. When applying lactovegetarians diet in conjunction with a specialized product "Meat Altai maral" complications and side effects were not identified.

The results of biochemical studies are shown in table 1. In the table of values shows that at the beginning of the study one hundred is isticheskie significant differences in performance between the analyzed groups was not observed.

On day 33 observations noted that patients of the main group there was a statistically significant decrease in total cholesterol compared with baseline. These changes indicate a positive effect of the applied therapy. Also statistically significantly decreased the content of β-lipoproteins and low-density lipoprotein (the main transport form of atherogenic cholesterol), which was one of the reasons for the decrease in total cholesterol. In the main group there was a significant decrease in haemoglobin. The level of triglycerides in patients of the main group were statistically significantly increased, which in this case shows what is happening lipolytic processes (the process of mobilization and transport of neutral fat and its subsequent cleavage), the completion of which was the reduction in body weight in patients of this group on average 2.5 kg (1.5 to 3.5 kg). In patients of group II, the level of triglycerides by the end of the study decreased, and the weight loss was on average 1.6 kg (0.5 kg to 2.7 kg), which characterizes the end of lipolytic processes. All these data indicate a higher efficiency of the proposed diet compared to a mixed diet No. 10C.

Sources of information

1. Klimov A.N., Nikulicheva N.G. Lipids, lipoproteins and aroclors. - SPb.: Peter Press. 1995. - 304 S. - (series "Practical medicine").

2. Therapeutic guide Washington University Lane. from English. Ed. Mvuli, Awalan. - M.: Practice, 1995.

3. Pancakes N.P., Gromov AG, D. N. Sinev. Handbook of drugs with the recipe. - SPb.: Gippokrat. - 768 S.

4. Clinical pharmacology. Volume 2. Ed. Droulers, Pninit.- M. 1993. - 672 S.

5. Mashkovsky PPM Medicines. In two parts. Part II. - 12th ed. revised and enlarged extra - M.: Medicine. 1993. - 688 S.

6. Mgil. Visual pharmacology. TRANS. from English. Ed. Magomedova. - M.: GEOTAR MEDICINE, 1999. - 104 S.

7. Guide the practitioner. 2000 diseases from a to z, Ed. Intensiva, Egolemanova. - M.: GEOTAR MEDICINE. 1999. - 1296 S.

8. Guide nutrition / edited Ayubjanovich, SPb.: Peter, 2001. - 539 S.

9. Patent RU №2201239. A means of having antihyperlipidemic activity, food additive on the basis and method for the treatment of lipid metabolism disorders in patients.

Table 1
Comparative evaluation of (X±m) of biochemical parameters of blood in the dynamics (the numerator to the beginning of the study, the denominator is the completion of the study)
IndicatorsGroupp
maincomparison
X±mX
Cholesterol(3,35-5.0 mmol/l)
β-lipoproteins (3,5-6,0 g/l)
Low-density lipoprotein (<3 mmol/l)
High-density lipoprotein (>1 mmol/l)
Triglycerides (<4.5 mmol/l)
The atherogenic index (<3 mmol/l)
Note: * statistical significance of the differences of the indicators analyzed in the groups at the beginning and end of the observation

The method of treatment of disorders of lipid metabolism and body weight reduction in patients with cardiovascular disease through diet, characterized in that diet therapy is conducted on the basis of lactovegetarians diet and provides an introduction proteins 67-79 g per day, of these animals 48-57%, fat 32-49 grams per day, of which animals 40-52%, carbohydrates 240-257 grams per day, cholesterol 40-268 mg per day, fiber 18-20 grams per day of dietary fiber 150 mg daily, potassium (K) 4567-6433 mg per day of magnesium (Mg) 535-693 mg per day, vitamin E 44-53 mg per day, arginine of 3.9 to 5.2 grams per day, dehydrated powder meat deer 1200 mg per day, microcrystalline cellulose 900 mg per day, with the duration of therapy is 33 days..



 

Same patents:

FIELD: medicine.

SUBSTANCE: as additional components, a new medicinal form contains stearic acid or its pharmaceutically acceptable salt, succinic acid or its pharmaceutically acceptable salt, microcrystalline cellulose, magnesium carbonate, starch and hydroxypropyl cellulose.

EFFECT: extended range of storage-stable preparations of 3-oxy-6-methyl-2-ethylpyridine as solid oral dosage forms without by-effects of existing preparations.

14 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: invention concerns a solid oral dosage form composition containing therapeutically effective amount of aliskiren or its pharmaceutically acceptable salt in amount exceeding 46 wt %. The oral dosage form represents a tablet or a film-coated tablet. Aliskiren tablet is made by wet granulation with using mixed organic solvents or organic binding solutions.

EFFECT: elimination of aqueous granulation provides high stability of the dosage form of aliskiren and prolonged shelf-life.

18 cl, 2 ex

Antiishemic agent // 2384327

FIELD: medicine.

SUBSTANCE: there is offered to apply 4-(2-hydroxyethyl)phenol(n-thyrozol) as a medicinal agent with anti-ischemic properties.

EFFECT: intravenous introduction of n-thyrozol improves the survival rate of animals with old myocardial ischemia and reperfusion, reduces a region of myocardial ischemia, and enables higher integrity of myocardial tissue.

3 tbl, 3 ex

Triazole derivative // 2383536

FIELD: chemistry.

SUBSTANCE: described are novel triazole derivatives with general formula where values of radicals are given in the formula of invention, a pharmaceutical composition containing said derivatives, and a method of treating autoimmune diseases. Compounds with general formula (1) and their pharmaceutically acceptable salts have inhibition effect on S1P and its Edg-1 receptor (S1P1).

EFFECT: possibility of use as a pharmaceutical product.

43 cl, 10 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: for treatment of left ventricle hypertrophy (HLV) in patients with coronary disease in combination with hypertension during 6 months standard drug therapy, consisting of IATA, beta-blocker, aspirin and stanin is realised. Additionally ivabradin in day dose 5 - 15 mg is introduced in two intakes daily.

EFFECT: method ensures transformation of HLV in concentric remodeling of left ventricle and in such way reduces degree of cardiovascular complications risk.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: pharmaceutical compositions include divalent, namely calcium, magnesium or zinc salt, of pravastatin or fluvastatin and omega-3 fat, for prevention, reduction or treatment of increased cholesterol levels, atherosclerosis, hyperlipidemia, cardio-vascular disorders and diseases, coronary heart disease and/or cerebrovascular disease.

EFFECT: improved bioavailability of compositions, easily obtained and introduced.

40 cl, 33 dwg, 2 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology, and concerns treating of myocardial infarction (MI). That is ensured by primary transcutaneous transluminal coronary angioplasty with underlying standard conservative therapy is followed with myocardial unload with beta-blocker Carvedilol. Said myocardial unload is combined with introduction of Levosimendan at first administered as a bonus intravenously at 16 mcg/kg during 10 min, and then in stable AP it is infused intravenously within 20-38 hours in total dose 12.5 mg/kg at the rate 0.05 to 0.2 mcg/kg/minutes.

EFFECT: method provides higher survival rate and ensured clinical compensation in the MI patients of elderly and senile age with cardiac failure complications due to combination of endovascular revascularisation and myocardial unload with underlying introduction of inotropic stimulator Levosimendan in the developed doses and regimen.

2 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medicine, neurology section and can find application in neurologic and neural rehabilitation clinic in treating the patients with aphasia. That is ensured by administration of acatinol memantin according to certain schedule with underlying logopedic lessons. Within the first week of therapy, the dose is 5 mg/day in the morning at mealtime. Within the second week, the dose is 10 mg/days, with 5 mg in the morning and in the evening. Within the third week, the dose is increased to 15 mg/days, with 10 mg in the morning and 5 mg in the evening. Within the fourth week, the dose is increased to 20 mg/days. And the maintenance dose makes 20 mg/days.

EFFECT: method provides effective treatment of apparent rough aphasia caused by disordered cerebral blood flow.

1 ex, 2 tbl

FIELD: chemistry.

SUBSTANCE: novel isoquinoline derivatives are described by general formula I, where q equals zero; p equals zero or one; Ra is -COOH or WR8; under the condition that, if Ra is -COOH, then p equals zero, and if Ra is -WR8, then p equals one; W is selected from an oxygen atom and -NR9-, where R9 is selected from a group consisting of a hydrogen atom, acyl and alkyl; and R8 is selected from a group consisting of a hydrogen atom and alkyl; R1 is selected from a group consisting of a hydrogen atom, alkyl, alkyl substituted with one group selected from alkoxy and dialkylamino, a halogen atom, heteroaryl containing up to six carbon atoms, one of which is nitrogen, aminoacyl, aryl, aryl substituted with alkyl, and -XR6, where X is an oxygen atom, -S(O)n- or -NR7, where n equals zero, one or two, R6 is selected from a group consisting of alkyl, aryl, aryl substituted with one group selected from a halogen atom, alkoxy, alkylcarbonylamino and alkylsulfonamide, heteroaryl, containing up to six carbon atoms, one of which is nitrogen, and R7 is a hydrogen atom or aryl; R2 and R3 are independently selected from a group consisting of a hydrogen atom, amino, amino substituted with alkoxy-substituted phenylsulfonyl, alkyl, alkyl substituted with up to three times by a halogen atom, aryl, halogen atom -NR6C(O)NR6R6, and -XR6, where X is an oxygen atom or -S(O)n-, where n equals zero, one or two, each of the substitutes R6 is independently selected from a group consisting of hydrogen, alkyl, alkyl substituted with aryl, aryl , aryl substituted with one or two groups selected from a halogen atom, alkyl, alkyl substituted with up to three times by a halogen, alkoxy, alkoxy substituted with up to three times by a halogen, aryloxy substituted with a halogen, nitro, alkylsulfonamide, arylsulfonamide and alkyl-substituted arylsulfonamide, cycloalkyl, heteroaryl, containing up to six carbon atoms, one of which is nitrogen, under the condition that if X is -SO2-, R6 cannot be a hydrogen atom; or R2 and R3 together with carbon atoms to which they are bonded, are bonded with formation of an aryl group; R4 and R5 are independently selected from a hydrogen atom or aryl; R is selected from a group which includes a hydrogen atom, deuterium and methyl; R' is selected from a group consisting of a hydrogen atom, deuterium, alkyl or alkyl substituted with one group selected from hydroxyl, amino, carboxyl, aryl, aryl substituted with one hydroxyl and heteroaryl, containing up to five carbon atoms, two of which can be nitrogen; on the other hand, R and R' and the carbon atom to which they are bonded can be bonded with formation of cycloalkyl; R" is formed from a hydrogen atom and alkyl, or R" together with R' and the nitrogen atom to which they are bonded can be bonded with formation of a heterocyclic group containing up to six carbon atoms, one of which is nitrogen; R'" is selected from a group consisting of hydroxyl, alkoxy, alkoxy substituted with aryl, acyloxy, aryl, -S(O)n-R10, where R10 is hydrogen, and n is zero; or its pharmaceutically acceptable salts, esters or amides; under the condition that restrictive conditions given in paragraph 1 of the formula of invention are met. The invention also relates to specific produced and described compounds, a pharmaceutical composition based on compounds with general formula I, a method of treating, preventing and pretreatment using said pharmaceutical composition, a method of inhibiting activity of hydrolase enzyme, based on taking an effective amount of a formula I compound, a composition for preventing and pretreatment, based on formula I compound and erythropoietin.

EFFECT: new isoquinoline derivatives have useful biological properties.

53 cl, 4 tbl, 253 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to chemical-pharmaceutical industry and concerns pharmaceutical composition for prevention and treatment of diseases and disease states connected with metabolic pathways of cycloxygenase-2 (CG-2) and 5-lipooxygenase (5-LO), which contains mixture of extract obtained from Scutellariae and enriched with flavonoids with free B-ring, which include baicalein, and extract obtained from Acacia and enriched with flavans, which include catechine and epicatechine. Claimed invention also relates to method of body weight loss and control over glucose level in blood. Methods by claimed invention include introduction to person, who needs it, of efficient amount of composition by claimed invention together with pharmaceutically acceptable carrier. Claimed invention mainly relates to prevention and treatment of diseases and states connected with metabolic pathways of cycloxygenase-2 (CG-2) and 5-lipooxygenase (5-LO), including, but not confining to it, stopping discomfort and pain in joints, induced by such states as osteoarthritis, rheumatoid arthritis and other injuries caused by overload.

EFFECT: composition possesses high efficiency.

35 cl, 22 ex, 15 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula

or

or to their pharmaceutically acceptable salts, where ring A, R2, R3, R4 and X are as defined in the description. The disclosed compounds are useful as 11βHSD1 inhibitor. The invention also relates to a pharmaceutical composition, an agent for treating or preventing pathology related to glucocorticoids, a 11βHSD1 inhibitor containing the disclosed compound or its pharmaceutically acceptable salt, and use of the disclosed compounds.

EFFECT: compounds are highly effective.

40 cl, 48 tbl, 191 ex

FIELD: medicine.

SUBSTANCE: invention relates to compounds of general formula (I) and their pharmaceutically acceptable salts and pharmaceutically acceptable asters, possessing activity with respect to LXRα and/or LXRβ receptors. Compounds can be applied for treatment and prevention of diseases mediated by LXRα and/or LXRβ receptors, namely: increased level of lipids and cholesterol level, atherosclerotic diseases, diabetes, metabolic syndrome, dyslipidermia, sepsis, inflammatory diseases, pancreatitis, liver cholestasis/fibrosis, and diseases which include inflammatory component, such as Alzheimer's disease and reduced/improvable cognitive function. In general formula n represents integer number from 0 to 3; R1 is independently selected from group consisting of halogen, -CN, -NO2, -SO2Me, lower alkyl, -OR11, pyperidinyl and -N(R11)(R11), where R11 is independently selected from lower alkyl and H, X1, X2, X3 and X4 are independently selected from nitrogen and carbon, on condition that, not more than two of X1, X2, X3 and X4 can simultaneously represent nitrogen, and in case when two of X1, X2, X3 and X4 represent nitrogen, n represents 0,1 or 2; k represents integer number 0 or 1; R2 represents H; R3 represents H, lower alkyl or halogen; R4 represents aryl, heteroaryl, lower alkylaryl or lower alkylheteroaryl, each of which is optionally substituted with substituents in amount from one to five, which are independently selected from group consisting of halogen, lower alkyl, -OR41, lower alkinyl and NR42R43, where R41 represents lower alkyl, R42 and R43 independently on each other represent hydrogen or lower alkyl, or NR42R43 represents pyrrolidinyl, or R4 represents lower alkyl; R5 is selected from group, heteroaryl, consisting of and , said aryl and heteroaryl being optionally substituted in one or more positions with one or more substituents, independently selected from group consisting of H, halogen, lower alkyl and (CH2)VR53, where R51 is selected from group consisting of H, lower alkyl, lower alkenyl and lower alkylaryl, said lower alkylaryl is optionally substituted in one or more positions with one or more lower alkyl, -CN, halogen, group -COOR54 and group -CH2OR54, where R54 represents lower alkyl or H; R52 represents lower alkyl or -H; R53 represents H, lower alkyl, C3-C6-cycloalkyl, -COOR55, -N(R55)(R56), -CH2OH, -CN, CF3, -CONH2 or -CH2OR55, where R55 is independently selected from group consisting of lower alkyl, -H, -C(O)aryl or -C(O)-lower alkyl, and R56 is selected from group consisting of H, lower alkyl, -C(O)CF3, -C(O)aryl, -C(O)-lower alkyl and lower alkylaryl, and where said aryl and lower alkylaryl are optionally substituted in one or more positions with one or more lower alkyl, halogen, group COOR57 and group -CH2OR57, where R57 represents lower alkyl or -H, or R55 and R56 together with atom to which they are bound, form ring system; or R53 represents aryl, which can be optionally substituted with benzyloxy, carboxy, lower alkoxycarbonyl, hydroxy-(lower alkyl), halogen, carbamoyl, (lower alkyl)carbamoyl, di-(lower alkyl)carbamoyl, m represents integer number from 0 to 2; v represents integer number from 0 to 4; where term "lower alkyl" separately or in combination with other groups refers to branched or linear monovalent alkyl radical, containing from one to six carbon atoms, where term "aryl" separately or in combination with other groups refers to phenyl or naphthyl, and where term "hetyeroaryl" refers to aromatic 5- or 6-member ring, which can include 1-3 heteroatoms selected from nitrogen, oxygen and/or sulphur, and which can be condensed with phenyl group.

EFFECT: increase of compound application efficiency.

38 cl, 5 dwg, 137 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical compositions include divalent, namely calcium, magnesium or zinc salt, of pravastatin or fluvastatin and omega-3 fat, for prevention, reduction or treatment of increased cholesterol levels, atherosclerosis, hyperlipidemia, cardio-vascular disorders and diseases, coronary heart disease and/or cerebrovascular disease.

EFFECT: improved bioavailability of compositions, easily obtained and introduced.

40 cl, 33 dwg, 2 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel hexafluoroisopropanol substituted derivatives of cyclohexane of formula (I) with LXRα- and/or LXRβ agonist modulation properties, as well as to their pharmaceutically acceptable salts. In formula (I) R1 denotes hydrogen, lower alkyl, fluoro-lower alkyl, lower alkyl-carbonyl, fluoro-lower alkyl-carbonyl, phenyl-lower alkyl, C3-C6-cycloalkyl-lower alkyl, C3-C6-cycloalkylcarbonyl or C3-C6-cycloalkyl-lower alkyl-carbonyl; R2 denotes hydrogen or lower alkyl; R3 denotes lower alkyl, phenyl-lower alkyl, where phenyl is possibly substituted with lower alkoxycarbonyl, lower alkoxycarbonyl, or if X represents a single bond and m is not equal to 0, R3 can also denote a hydroxy group; R4 denotes phenyl or heterocyclyl, where heterocyclyl is a five-member aromatic heterocyclic ring containing two heteroatoms selected from nitrogen and sulphur, optionally substituted with 1-3 substitutes independently selected from a group which includes lower alkyl and halogen; X denotes a single bond, SO2, CO or C(O)O; m equals 0, 1, 2 or 3; n equals 0 or 1. The invention also relates to a pharmaceutical composition containing formula (I) compounds.

EFFECT: novel compounds have useful biological properties.

20 cl, 35 ex

FIELD: chemistry.

SUBSTANCE: compounds of formula (I): , where: R1 is H, C1-6alkyl, C3-6cycloalkyl, phenyl, naphthyl; where the said C1-6alkyl can possibly be substituted with one or two substitutes selected from OH, NH2, guanidine, carbamoyl, COOH, C1-6alkoxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-C6alkylcarbonylamino, C1-6alkylS(O)a, where a equals 0-2, C3-6cycloalkyl, phenyl or indolyl; and where any of the said phenyl, indolyl can possibly be substituted with one or two substitutes selected from halogen, OH, C1-6alkyl, C1-6alkoxy; R2, R5 independently represents H, branched or straight C1-6alkyl, C3-6cycloalkyl, phenyl or naphthyl; where the said C1-6alkyl can possibly be substituted with one or more OH, NH2, guanidine, CN, carbamoyl, COOH, C1-6alkoxy, phenylC1-6alkoxy, naphthylC1-6alkoxy, indolyl, imidazolyl, naphthyl, (C1-C4)3Si, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkylS(O)a, C3-6cycloalkyl, phenyl, phenyl-C1-6alkylS(O)a, naphthyl-C1-6alkylS(O)a, where a equals 0-2; where any of phenyl, naphthyl, indolyl, imidazolyl can possibly be substituted with one or two substitutes selected from halogen, OH, C1-6alkyl, C1-6alkoxy; R3 is H, C1-6alkyl, halogen, C1-6alkoxy or C1-6alkylS-; R4 is H, C1-6alkyl, halogen, C1-6alkoxy; R6 is H, C1-6alkyl, phenylC1-6alkyl, naphthylC1-6alkyl; where R5, R2 can form a cyclopropane, cyclopentane ring, where R6, R2 can form a pyrrole ring; or its pharmaceutically acceptable salt; given the condition that the said compound is not 3-(R)-4-(R)-1-(phenyl)-3-[2-(4-fluorophenyl)-2-hydroxyethylsulphanyl]-4-[4-(N-{N-[(R)-1-(carboxy)-2-hydroxy)ethyl]carbamoylmethyl}carbamoylmethoxy)phenyl]-azetidin -2-one or 3-(R)-4-(R)-1-(phenyl)-3-[2-(4-flurophenyl)-2-hydroxyethylsulphanyl]-4-{4-N-((R)-α-{N-[(S)-1-(carboxy)-2-(hydroxy)ethyl]-carbamoyl}benzyl)carbamoylmethoxy]phenyl}azetidin-2-one.

EFFECT: obtaining compounds which are useful as cholesterol absorption inhibitors, enabling their use in pharmaceutical compositions.

18 cl, 136 ex

FIELD: medicine.

SUBSTANCE: present invention concerns new, selectable hybrid polypeptides expressing at least two hormonal activities containing a first biologically active module of a peptide hormone covalently bonded with at least one additional biologically active module of the peptide hormone.

EFFECT: polypeptides can be used as agents for treatment and prevention of metabolic diseases and disorders associated with overweight.

19 cl, 6 dwg, 6 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention is related to new compounds that comply with formula (I) , where: n is equal to 1, Ra, Ra', Rb, Rb', identical or different, mean atom of hydrogen or alkyl or cycloalkyl group, besides, Rb and Rb' may create carbon bridge having 4 links together with hydrogen atoms of cycle, to which they are connected, R1 means cyclohexyl group, R2 means 1,2,4-triazolyl group, R3 means 1-3 groups, selected from atoms of halogen, available in any position of cycle, to which they are connected, R5 means atom of hydrogen, R4 is selected from groups of formulas (a), (b) and (c), given below, mono- or polysubstituted with aryl group: (a), (b), (c), in which: p=0, 1, 2 or 3, m=0, 1 or 2, and either a) X means link -N(R10)-, where R10 is selected from: groups -CO-NR8R9, -COOR8, -(CH2)x-OR8, -(CH2)x-COOR8, -(CH2)x-COR8, in which x=1, 2, 3 or 4, heterocycloalkyl group, condensed with aryl group, cycloalkyl, aryl, heteroaryl, alkylaryl, -CO-alkyl, -CO-cycloalkyl, -CO-heterocycloalkyl, -CO-aryl, -CO-heteroaryl, -CO-alkylaryl, -SO2-alkyl, -SO2-cycloalkyl, -SO2-aryl, besides, alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl groups are unnecessarly substituted with one or several groups selected from atoms of halogen and groups R, R', OR, NRR', -CN, -COOR, COR; or R10 together with atom of nitrogen, to which it is connected, and with atom of carbon, available in any position of cyclic structure of formula (a), but not in neighboring position to mentioned atom of nitrogen, creates a bridge that contains 3-5 links, R8 and R9 are selected, independently from each other, from atom of hydrogen and alkyl or cycloalkyl groups; R and R' mean, independently from each other, atom of hydrogen or alkyl, cycloalkyl, aryl groups; or b) X means link - C(R6)(R7)-, where R6 is selected from the following: atom of hydrogen, atom of halogen, groups -(CH2)x-OR8, -(CH2)x-COOR8, -(CH2)x-NR8R9, -(CH2)x-CO-NR8R9 or -(CH2)x-NR8-COR9, in which x=0, 1, 2, 3 or 4, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl group, heterocycloalkyl group, condensed or non-condensed, available in spiro-position to cycle of formula (a), to which it is connected, heterocycloalkyl group, condensed with aryl group, besides, alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl groups are unnecessarily substituted with one or several groups selected from atoms of halogen and groups R, R', OR, NRR', -CO-NRR', -CN, -COOR, OCOR, COR, NRCOOR'; and heterocycloalkyl groups are unnecessarily condensed with aryl group; R7 is selected from atoms of hydrogen and halogen and alkyl, cycloalkyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl groups, -OR, -O-aryl, -O-alkylaryl, -O-alkylheteroaryl, groups -NRR', -CO-NRR', -NR-CO-R', -NR-CO-NRR', -NR-COOR', -NO2, -CN and -COOR, R8 and R9 are selected, independently from each other, from atom of hydrogen and alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl groups, -CO-alkyl, -CO-cycloalkyl, -CO-aryl, -(CH2)x-OR, where x=0, 1, 2, 3 or 4, besides, alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are unnecessarily substituted with one or several groups selected from atoms of halogen and groups R, R', OR, NRR', -CO-NRR', -CN, -COOR, OCOR, COR, NRCOOR'; or R8 and R9 create together cycloalkyl or heterocycloalkyl; R and R' mean, independently from each other, atom of hydrogen or alkyl, cycloalkyl, heterocycloalkyl, aryl, or may together create cycloalkyl or heterocycloalkyl; besides heteroaryl group represents aromatic group that contains from 5 to 10 atoms and from 1 to 4 heteroatoms, selected from nitrogen, oxygen or sulfur; heterocycloalkyl group represents cycloalkyl group, which contains from 5 to 10 atoms and contains from 1 to 4 heteroatoms selected from nitrogen, oxygen or sulfur; in the form of base or acid-additive salt, and also in the form of hydrate or solvate. Invention is also related to medicinal agent, to pharmaceutical composition, to application, to method of production, and also to compounds of formulas (IV) , (V), (VI), (XXVIII), (XXIX), (II).

EFFECT: production of new biologically active compounds, having activity of agonists of melanocortin receptors.

36 cl, 22 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: there are described derivatives of 1,3,4-oxadiazol-2-one of formula I and their pharmaceutically acceptable salts wherein ARYL represents phenyl which can have one substitute chosen from halogen; W represents chain or (CH2)m where m designates an integer 1 to 4; Z represents -O(CH2)n-, -(CH2)n-Y-(CH2)n- where Y designates O, n independently means an integer 1 to 5; X represents O or S; R1 represents C1-6 alkyl; R2 represents substituted phenyl where substitutes are chosen from the group including C1-6alkyl, C1-4perfluoralkyl. There are also described pharmaceutical composition, and method of treating a disease in mammal wherein said disease can be modulated by PPAR-delta receptor binding activity.

EFFECT: compounds possess agonist or antagonist activity with respect to PPAR-delta receptor.

9 cl, 2 tbl, 34 ex

FIELD: medicine.

SUBSTANCE: there is offered application of alpha-ketoglutaric acid or its pharmaceutically acceptable salt for manufacturing of a pharmaceutical preparation or a food or fodder additive for stimulating production of high-density lipids (HDL) in vertebrate animals, including human, and the relevant method for stimulating production of HDLs with alpha-ketoglutaric acid (or its salt) and pharmaceutically acceptable physical mixtures of alpha-ketoglutaric acid or its pharmaceutically acceptable salt and at least one amino acid.

EFFECT: there is disclosed statistically significant increase of HDLs concentration with decrease in total cholesterol, LDLs and triglycerides.

18 tbl, 3 ex, 7 cl

FIELD: chemistry.

SUBSTANCE: present invention relates to compounds of formula (I), their R and S isomers; or a mixture of R and S isomers; or pharmaceutically acceptable salts. Disclosed compounds can be used as a medicinal agent with agonist properties towards PPAR. In formula (I) and L represents (II) or (III); R1, R2, R3, Ya, R4a, R", Yb, R4b are hydrogen; R and R' are independently hydrogen, C1-C4alkoxy; n equals 0, 1 or 2; m equals 0, 1 or 2; X1 is a -Z-(CH2)P-Q-W group; X2 is -CH2-, -C(CH3)2-, -O- or -S-.

EFFECT: invention relates to a pharmaceutical composition, which contains the disclosed compound, to use of the pharmaceutical composition as a medicinal agent, to use of the disclosed compound in making the pharmaceutical composition.

13 cl, 35 ex

FIELD: veterinary science.

SUBSTANCE: invention refers to veterinary medicine and can be used in large cattle-breeding complexes, farms and private economies. Substance of the invention implies that intrauterine suppositories for vulvovaginitis treatment and prevention in cows contains Vivaton, "АСД-2ф", chemically pure lanolin as an emulsifier, and cocoa butter as an excipient in the ratio per one suppository as follows, g: Vivaton 1.0; chemically pure lanolin 1.0; "АСД-2ф" 0.5; Cocoa butter 8.0. The method of application of intrauterine agent for vulvovaginitis treatment and prevention in cows according to cl. 1 involves daily intrauterine introduction with therapeutic dosage of 2 suppositories twice a day during 3-5 days, and preventing dosage 1 suppository once a day during 2-3 days.

EFFECT: vulvovaginitis treatment and prevention in cows.

4 cl, 4 tbl, 2 ex

Up!